Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study)

Next Previous
Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivanib alaninate (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms BRISK-FL
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 27 May 2021 Results of a retrospective analysis of data from studies Bristol Myers Squibb and AbbVie Inc (NCT00858871and NCT01009593) to quantify the rate of tumour progression in patients receiving sorafenib published in the Journal of Hepatology
    • 11 Jun 2019 A Statistical model that allows personalised survival prediction following sorafenib treatment using data from 2 trials (NCT00858871 and NCT00699374) ;results published in the British Journal of Cancer
    • 26 Aug 2013 Results published in the Journal of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top